

The Right Choice for the Oncology Patient A Protected Lifeline



- Height: 5' 7"
- Weight: 143 lbs
- Heart Rate: 57
- BP: 118/68
- Creatinine: 0.7
- INR: 1.1
- No Fever

Case Study: Katie

Age: 37

Diagnosis and History:

- Recurrent breast cancer with lymph node involvement with prior diagnosis of breast cancer 3 years ago after lumpectomy

Reason for Vascular Access:

- Outpatient vascular access consult

Current Condition:

- She wants to discuss vascular access options
- She has issues with a catheter in her arm
- She states she is not ready for an implanted port or surgically placed catheter

Current Department:

- Outpatient

Social History:

- Supportive husband with two young children (ages 3 and 5). Leads an active lifestyle. She would "...like something that does not show and minimally affects her normal activities."

Current Therapy Needs:

- Short course chemotherapy, radiation therapy
- Anti-emetic medication (anti-nausea drugs)

Anticipated Length of Vascular Device Dwell Time:

- 4-12 weeks

Potential Therapy Needs:

- Hydration
- CT scan
- Other drugs
- Blood draws
- Electrolytes
- IV anti-emetics

Discharged with Line:

- Yes

Order:

- CVC to be inserted

A Protected Lifeline – The Oncology Patient

Why use a Central Venous Catheter?

- Chemotherapy treatment
- Potential for CT with contrast
- Insertion location is easy to hide
- Insertion location makes it easier to maintain normal activities
- Patient's choice

Insertion Site Options:

Internal Jugular, Subclavian, Axillary

Why use the ARROW® JACC?

- Based on options discussed, The Arrowg+ard Blue Advance™ JACC was requested by the patient because:
 - Patient feels that a chlorhexidine-treated JACC Catheter will decrease the risk of infection and thrombosis
 - Smaller catheter size decreases the risk of Venous Thrombosis
- Long-term central venous catheter without the tunnel or cuff
- Placement in the lower Internal Jugular, Axillary or Subclavian will best fit with her lifestyle

The Arrowg+ard Blue Advance™ JACC

The Arrowg+ard Blue Advance™ JACC (Jugular Axillo-subclavian Central Catheter) is the first and only long-term antimicrobial and antithrombogenic CVC. The ARROW JACC is a smaller French-size CVC protected with The Arrowg+ard Blue Advance™ Protection which helps prevent infection, occlusion, fibrin sheath and venous thrombosis for at least 30 days.^{1,2,3}

With these benefits, the ARROW JACC may dwell as long as your patient needs the catheter without ever changing to a secondary device. The ARROW JACC is designed to meet a patient's vascular access needs from the ICU through Outpatient Care. Get ready for a new paradigm in vascular access.



Discover the first and only long-term antimicrobial and antithrombogenic CVC.
Visit ARROWJACC.COM or call 800.523.8446

¹ *In vitro* data on file.

² As compared with uncoated Central Catheter, intravascular bovine model.

³ As compared to uncoated Central Line, *in vitro* model measuring flush pressure post exposure to human blood.

Rx only.

No correlation between *in vitro* / *in vivo* testing methods and clinical outcomes have currently been ascertained.

KDOQI is a trademark or registered trademark of the National Kidney Foundation, Inc.

Teleflex, Arrow, Arrowg+ard Blue Advance, and Never Settle are trademarks or registered trademarks of Teleflex Incorporated or its affiliates.

© 2018 Teleflex Incorporated. All rights reserved. MC-004534

ARROW®
NEVER SETTLE™